Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EDP-938 DDI Study with Tacrolimus, Dabigatran, Rosuvastatin and Midazolam
NCT04498741Phase 1Completed
- Sponsor
- Enanta Pharmaceuticals
- Start
- Jul 2020
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of zelicapavir in respiratory syncytial virus infection (RSV) (4 arms), sponsored by Enanta Pharmaceuticals. Primary endpoints: Cmax of tacrolimus with and without coadministration with EDP-938 up to 29 days, AUC of tacrolimus with and without coadministration with EDP-938 up to 29 days and 6 more. Started Jul 2020; status: completed.
02
Drugs
zelicapavir
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT04498741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04498741.